1. A pharmaceutical preparation suitable for use in a mammalian patient, comprising at least 10° mesenchymal stromal cells and a pharmaceutically acceptable carrier, wherein the mesenchymal stromal cells have replicative capacity to undergo (a) at least 10 population doublings in cell culture with less than 25 percent of the cells undergoing cell death, senescing or differentiating into non-MSC cells by the tenth doubling, or (b) at least 5 passages in cell culture with less than 25 percent of the cells undergoing cell death, senescing or differentiating into fibroblasts by the fifth passage, wherein the mesenchymal stromal cells are obtained by in vitro differentiation of a hemangioblast cell into a mesenchymal stromal cell.